Combination Sitravatinib and Nivolumab Boosts Outcomes in Advanced Kidney Cancer

In patients with advanced clear cell renal cell carcinoma, an optimal sitravatinib dose combined with a fixed dose of nivolumab improved outcomes in a phase 1-2 trial.

Related Keywords

California ,United States ,Houston ,Texas ,Fox Chase ,Pennsylvania ,Philadelphia ,Pavlos Msaouel ,Matthew Zibelman ,University Of Texas Md Anderson Cancer Center ,Reuters Health ,Cancer Center ,Science Translational ,Fox Chase Cancer Center ,Mirati Therapeutics ,San Diego ,Science Translational Medicine ,Malignant Kidney Neoplasm Renal Cell Cancer Rcc Carcinoma Of The ,Renal Cell Carcinoma ,Dcc ,Biologic Therapy ,Iologics ,Immunotherapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,